Medexus re­sub­mits NDA as it still looks to re­pur­pose a decades-old drug

The Ger­man drug­mak­er medac’s US sub­sidiary is hop­ing the sec­ond time is the charm for the com­pa­ny, as it is of­fi­cial­ly ask­ing the FDA once again to ap­prove its can­cer drug.

Medexus Phar­ma­ceu­ti­cals re­sub­mit­ted its re­quest for ap­proval of tre­o­sul­fan to be tak­en in com­bi­na­tion with flu­dara­bine, the com­pa­ny said Mon­day. The treat­ment is de­signed as a reg­i­men for al­lo­gene­ic hematopoi­et­ic stem cell trans­plan­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER